Arrowhead Pharmaceuticals · 13 hours ago
Summer Intern, CMC Process Development
Arrowhead Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative drugs for diseases with a genetic basis. The CMC Process Development Intern will support process development activities by conducting laboratory studies aimed at improving manufacturing efficiency and product quality, gaining hands-on experience in a collaborative environment.
BiotechnologyHealth CareNanotechnologyPharmaceutical
Responsibilities
Perform experiments to assess binding capacity, flow rate performance, FLP recovery, and FLP purity
Conduct reactions related to oligonucleotide synthesis
Analyze oligonucleotide samples using analytical techniques such as LC-MS
Maintain a well-documented laboratory notebook in accordance with established procedures
Interpret experimental results and support data-driven recommendations
Present findings from the summer research project during Process Development group meetings
Qualification
Required
Currently enrolled student at an accredited university or college, sophomore level or higher focused in Chemistry, Biochemistry, or a related field
Completion of at least one organic chemistry course
Interest in learning and applying a variety of laboratory instrumentation and techniques
Excellent verbal and written communication skills, including comfort presenting in group settings
Strong problem-solving and organizational skills
Proficiency in Microsoft Office applications
Ability to lift up to 40 lbs
Willingness and ability to spend 75% of the workday in walking around the facility and 25% at a desk
Ability to work in a laboratory environment for extended periods, including wearing required personal protective equipment (PPE)
Preferred
Prior exposure to LCMS techniques
Previous academic or industry research experience
Experience working with macromolecules such as oligonucleotides or proteins
Benefits
Competitive salaries
Excellent benefit package
Company
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Funding
Current Stage
Public CompanyTotal Funding
$2.45BKey Investors
Sarepta TherapeuticsSixth StreetSilence Therapeutics
2026-01-07Post Ipo Equity· $200M
2026-01-07Post Ipo Debt· $625M
2024-11-26Post Ipo Equity· $325M
Leadership Team
Christopher Anzalone
President and Chief Executive Officer
Recent News
2026-01-08
Company data provided by crunchbase